The European Perspective on Diabetes Prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE)
Free accessResearch articleFirst published online December, 2007
The European Perspective on Diabetes Prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE)
The prevalence of type 2 diabetes has increased dramatically in Europe, particularly in younger people. Nevertheless, jointly developed prevention strategies are still lacking. The development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE) project was initiated by the Technical University Dresden in response to this major public health concern of the European Union.
Within the IMAGE project, four specific objectives will be developed and implemented into clinical practice: a) joint European guidelines; b) a European training curriculum for prevention managers; c) European standards for quality control of diabetes prevention programmes; and d) a European e-health training portal for prevention managers.
This three-year-project began in June 2007. At the time of writing, 32 institutions from 16 countries have become involved.
The development of competent guidelines and education programmes, as well as the establishment of quality standards for the primary prevention of type 2 diabetes, should significantly enhance the ability of healthcare professionals to respond swiftly to its drastic increase and its burden to society.
1. Valensi PSchwarz PEH, Hall Met al.Pre-diabetes essential action: a European perspective. Diabetes Metab2005;31:606–20.
2.
2. Lammi NTaskinen O, Molchanova Eet al.A high incidence of type 1 diabetes and an alarming increase in the incidence of type 2 diabetes among young adults in Finland between 1992 and 1996. Diabetologia2007;50:1393–400.
3.
3. Nestle M.Preventing childhood diabetes: the need for public health intervention. Am J Public Health2005;95:1497–9.
4.
4. Zimmet P.The burden of type 2 diabetes: are we doing enough?Diabetes Metab2003;29(4 Pt 2):609–18.
5.
5. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet1999;354:617–21.
6.
6. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care2003;26(1):61–9.
7.
7. Kengne APPatel AHow important is diabetes as a risk factor for cardiovascular and other diseases in older adults?PLoS Med2006;3:e424.
8.
8. Rappaport JFonseca VCase-based study: from prediabetes to complications – opportunities for prevention. PLoS Med2005;2(2):e40.
9.
9. Schwarz PEHSchwarz J, Schuppenies Aet al.Development of a diabetes prevention management program for clinical practice. Public Health Rep2007;122:258–63.
10.
10. Tuomilehto J.Counterpoint: Evidence-based prevention of type 2 diabetes: the power of lifestyle management. Diabetes Care2007;30:435–8.
11.
11. Knowler WCBarrett-Connor E, Fowler SEet al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002;346(6):93–403.
12.
12. Tuomilehto JLindström J, Eriksson JGet al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343–50.
13.
13. Chiasson JLJosse RG, Gomis Ret al.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002;359:2072–7.
14.
14. Pan XRLi GW, Hu YHet al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care1997;20:537–44.
15.
15. Snitker SWatanabe RM, Ani Iet al.Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care2004;27:365–8.
16.
16. Torgerson JSHauptmann J, Boldrin MNet al.Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care2004;27:155–61.
17.
17. Ramachandran ASnehalatha C, Mary Set al.The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia2006;49:289–97.
18.
18. Lindström J, Ilanne-Parikka P, Peltonen Met al.Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673–9.
19.
19. Saaristo TPeltonen M, Keinänen-Kiukaanniemi Set al.National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health2007;66:101–12.
20.
20. Schwarz PEHSchwarz J, Bornstein Set al.Prevention of type 2 diabetes: what challenges do we have to address?J Public Health2005;13:303–08.
21.
21. BMGF. EUConference on Prevention of Type 2 Diabetes - Conference Report. Paper presented at: EU Conference on Prevention of Type 2 Diabetes, 2006; Vienna.
22.
22. Benterbusch REberhard C, Koesling S, et al.Sachsen. Gesundheitsziele im Föderalismus – Programme der Länder und des Bundes. Vol 1. Berlin: Schriftenreihe der GVG; 55; 2007:191.
23.
23. Schwarz PEHGruhl U, Bornstein Set al.IMAGE – Development and Implementation of a European Guideline for Diabetes Prevention and of a Curriculum for prevention Managers including the Establishment of Quality Control Standards on an E-Health Training Programme. Diabetes Vasc Disease Res2007;4(suppl 1):S117.
24.
24. Schwarz PEBornstein RS.Pre-diabetes and metabolic syndrome in Germans. Horm Metab Res2006;38:359.
25.
25. Roubideaux, Buchwald D, Beals Jet al.Measuring the quality of diabetes care for older American Indians and Alaska natives. Am J Public Health2004;94(1):60–5.
